FDA Shoots Down Lipocine’s TRT Drug for Third Time

Drug Industry Daily
A A
Lipocine has received a third complete response letter from the FDA for its novel oral testosterone replacement therapy Tlando for treatment of male hypogonadism.

To View This Article:

Login

Subscribe To Drug Industry Daily